Last checked at 26 Apr 2019 09:56
hVIVO plc
("hVIVO" or the "Company")
2018 Annual Report and Financial Statements and Annual General Meeting 2019
London, UK - 26 April 2019: hVIVO plc (AIM: HVO), announces that the following documents have been sent to shareholders.
· Annual Report and Financial Statements for the year ended 31 December 2018
· Notice of Annual General Meeting ("AGM") 2019
· Form of Proxy for the AGM
In accordance with AIM Rule 26, these documents are available on Company's website at, http://hvivo.com/investors/financial-reports/.
The AGM is scheduled to be held at 10.00am BST on Thursday 30 May 2019 on 3rd Floor, Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX.
For further information please contact:
hVIVO plc | |
Trevor Phillips (Executive Chairman) | +44 207 756 1300 |
Shelley Fraser (Finance Director & Company Secretary) Fleur Wood (EVP, Investor Relations & Communications)
|
|
Numis Securities Limited | +44 207 260 1000 |
Freddie Barnfield / Huw Jeremy (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2700 volunteers.